End-of-treatment and serial PET imaging has prognostic value and clinical utility in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R - Response to Adams <i>et al.</i>

Melani, Christopher; Roschewski, Mark; Wilson, Wyndham H

End-of-treatment and serial PET imaging has prognostic value and clinical utility in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R - Response to Adams et al.

Melani, Christopher; Roschewski, Mark; Wilson, Wyndham H.

Afiliação

Melani C; Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Roschewski M; Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Wilson WH; Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA wilsonw@mail.nih.gov wyndham.wilson@gmail.com.

Haematologica ; 103(8): e382, 2018 08.

Article em En | MEDLINE | ID: mdl-30065020

Assuntos

Fluordesoxiglucose F18; Linfoma de Células B; Ciclofosfamida; Seguimentos; Humanos; Tomografia por Emissão de Pósitrons; Prognóstico; Vincristina

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma de Células B / Fluordesoxiglucose F18 Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google